Features and benefits
The key features of MIRCERA are listed below. A summary of the information and clinical evidence supporting each of these statements can be viewed on separate pages by clicking on the statement.
The safety of MIRCERA is comparable to shorter-acting erythropoiesis-stimulating agents (ESAs).
Successful conversion to once-monthly MIRCERA can be achieved with consistent Hb stability.
- © 2010 F.Hoffmann-La Roche Ltd. The information provided on this Website is intended for non-US healthcare professionals. Use and access of this site is subject to the terms and conditions. Mircera is a registered trademark of F.Hoffmann-La Roche Ltd. Mircera - Brief Prescribing Information * This image represents an artists view of a possible structure for Mircera